Novel three-drug combo shows promise in advanced HER2-negative breast cancer treatment

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

Related Keywords

California ,United States ,New York ,Ireland ,Miami ,Florida ,American ,James Leatherman ,Avonne Oconnor ,Alexei Hernandez ,Johns Hopkins ,Michelle Rudek ,Elizabeth Engle ,Christine Rafie ,Evanthia Roussos Torres ,Joseph Tandurella ,Elizabeth Jaffee ,Roisin Connolly ,Los Angeles ,Robert Anders ,Chenguang Wang ,Vered Stearns ,Qingfeng Zhu ,Elana Fertig ,Roussos Torres ,Sarah Shin ,Ludmila Danilova ,University Of Pittsburgh Cancer Institute ,University College Cork ,Yale Cancer Center ,Kimmel Cancer Center ,Ohio State University ,Home Group ,Cancer Therapy Evaluation Program ,Johns Hopkins University School Of Medicine ,National Cancer Institute ,Johns Hopkins Kimmel Cancer Center ,Parker Institute ,Genentech ,Johns Hopkins University ,University Of Miami Miller School Medicine ,University Of Pittsburgh Hillman Cancer Center ,Johns Hopkins Kimmel Cancer ,Nature Cancer ,Southern California Keck School ,Johns Hopkins University School ,Weill Cornell Medicine ,Melinda Downs ,Avonneo Connor ,Miami Miller School ,Pittsburgh Cancer Institute ,Hillman Cancer Center ,Cedars Sinai Cancer ,Ohio State ,Medical Home Group ,Break Through Cancer ,Breast Cancer ,Dancer ,Growth Factor ,Ormone ,Immune Response ,Immunotherapy ,Medicine ,Eceptor ,Research ,Humor ,